Mechanisms of action of glatiramer acetate in multiple sclerosis

Oliver Neuhaus, Cinthia Farina, Hartmut Wekerle, Reinhard Hohlfeld

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

Glatiramer acetate (GA, Copaxone [Teva Pharmaceuticals, Kansas City, MO], formerly known as copolymer-1) and interferon- (IFN)-β are both used for the immunomodulatory treatment of multiple sclerosis, but they act in different ways. Four major mechanisms of GA have been identified: 1) competition with myelin-basic protein (MBP) for binding to major histocompatibility complex (MHC) molecules; 2) competition of GA/MHC with MBP/MHC for binding to the T-cell receptor; 3) partial activation and tolerance induction of MBP-specific T cells (action as an altered peptide ligand); and 4) induction of GA-reactive T-helper 2- (TH2)-like regulatory cells. Of these four mechanisms, 1 and 2 presumably occur only in vitro and are therefore irrelevant for the in vivo effects of GA. In contrast, mechanisms 3 and 4 could occur in vivo and both could contribute to the clinical effects of GA.

Original languageEnglish
Pages (from-to)702-708
Number of pages7
JournalNeurology
Volume56
Issue number6
Publication statusPublished - Mar 27 2001

Fingerprint

Myelin Basic Protein
Major Histocompatibility Complex
Multiple Sclerosis
T-Cell Antigen Receptor
Protein Binding
Interferons
Ligands
T-Lymphocytes
Peptides
Pharmaceutical Preparations
Glatiramer Acetate

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Neuhaus, O., Farina, C., Wekerle, H., & Hohlfeld, R. (2001). Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology, 56(6), 702-708.

Mechanisms of action of glatiramer acetate in multiple sclerosis. / Neuhaus, Oliver; Farina, Cinthia; Wekerle, Hartmut; Hohlfeld, Reinhard.

In: Neurology, Vol. 56, No. 6, 27.03.2001, p. 702-708.

Research output: Contribution to journalArticle

Neuhaus, O, Farina, C, Wekerle, H & Hohlfeld, R 2001, 'Mechanisms of action of glatiramer acetate in multiple sclerosis', Neurology, vol. 56, no. 6, pp. 702-708.
Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001 Mar 27;56(6):702-708.
Neuhaus, Oliver ; Farina, Cinthia ; Wekerle, Hartmut ; Hohlfeld, Reinhard. / Mechanisms of action of glatiramer acetate in multiple sclerosis. In: Neurology. 2001 ; Vol. 56, No. 6. pp. 702-708.
@article{fb09325c4d07477fa406cfef9a14c350,
title = "Mechanisms of action of glatiramer acetate in multiple sclerosis",
abstract = "Glatiramer acetate (GA, Copaxone [Teva Pharmaceuticals, Kansas City, MO], formerly known as copolymer-1) and interferon- (IFN)-β are both used for the immunomodulatory treatment of multiple sclerosis, but they act in different ways. Four major mechanisms of GA have been identified: 1) competition with myelin-basic protein (MBP) for binding to major histocompatibility complex (MHC) molecules; 2) competition of GA/MHC with MBP/MHC for binding to the T-cell receptor; 3) partial activation and tolerance induction of MBP-specific T cells (action as an altered peptide ligand); and 4) induction of GA-reactive T-helper 2- (TH2)-like regulatory cells. Of these four mechanisms, 1 and 2 presumably occur only in vitro and are therefore irrelevant for the in vivo effects of GA. In contrast, mechanisms 3 and 4 could occur in vivo and both could contribute to the clinical effects of GA.",
author = "Oliver Neuhaus and Cinthia Farina and Hartmut Wekerle and Reinhard Hohlfeld",
year = "2001",
month = "3",
day = "27",
language = "English",
volume = "56",
pages = "702--708",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Mechanisms of action of glatiramer acetate in multiple sclerosis

AU - Neuhaus, Oliver

AU - Farina, Cinthia

AU - Wekerle, Hartmut

AU - Hohlfeld, Reinhard

PY - 2001/3/27

Y1 - 2001/3/27

N2 - Glatiramer acetate (GA, Copaxone [Teva Pharmaceuticals, Kansas City, MO], formerly known as copolymer-1) and interferon- (IFN)-β are both used for the immunomodulatory treatment of multiple sclerosis, but they act in different ways. Four major mechanisms of GA have been identified: 1) competition with myelin-basic protein (MBP) for binding to major histocompatibility complex (MHC) molecules; 2) competition of GA/MHC with MBP/MHC for binding to the T-cell receptor; 3) partial activation and tolerance induction of MBP-specific T cells (action as an altered peptide ligand); and 4) induction of GA-reactive T-helper 2- (TH2)-like regulatory cells. Of these four mechanisms, 1 and 2 presumably occur only in vitro and are therefore irrelevant for the in vivo effects of GA. In contrast, mechanisms 3 and 4 could occur in vivo and both could contribute to the clinical effects of GA.

AB - Glatiramer acetate (GA, Copaxone [Teva Pharmaceuticals, Kansas City, MO], formerly known as copolymer-1) and interferon- (IFN)-β are both used for the immunomodulatory treatment of multiple sclerosis, but they act in different ways. Four major mechanisms of GA have been identified: 1) competition with myelin-basic protein (MBP) for binding to major histocompatibility complex (MHC) molecules; 2) competition of GA/MHC with MBP/MHC for binding to the T-cell receptor; 3) partial activation and tolerance induction of MBP-specific T cells (action as an altered peptide ligand); and 4) induction of GA-reactive T-helper 2- (TH2)-like regulatory cells. Of these four mechanisms, 1 and 2 presumably occur only in vitro and are therefore irrelevant for the in vivo effects of GA. In contrast, mechanisms 3 and 4 could occur in vivo and both could contribute to the clinical effects of GA.

UR - http://www.scopus.com/inward/record.url?scp=0035957307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035957307&partnerID=8YFLogxK

M3 - Article

C2 - 11288751

AN - SCOPUS:0035957307

VL - 56

SP - 702

EP - 708

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -